Europe
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 21, 2020.
The European Society for Medical Oncology (ESMO) Virtual Congress 2020 was this weekend, with numerous companies presenting clinical trial data and updates.
The overall survival benefit of Lynparza was shared this weekend, four months after the U.S. Food and Drug Administration approved it as a treatment for prostate cancer.
LAVA Therapeutics is now financially poised to advance their bispecific antibodies to engage Vγ9Vδ2 T cells in the fight against cancer thanks to an infusion of capital from an oversubscribed $83 million Series C financing.
Biopharma companies focused on oncology continue to release data that will be presented at the 2020 virtual meeting of the European Society of Medical Oncology.
It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies.
Regeneron and Sanofi broke new ground in treating advanced basal cell carcinoma with their anti-PD-1 inhibitor, Libtayo.
Roche launched its Elecsys Anti-SARS-CoV-2 S antibody test for markets that accept the CE Mark.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
PRESS RELEASES